DOCSLIB.ORG

"Enkephalinase" and of Ja and 6 Opioid Receptors in Rat Brain

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proc. Natl. Acad. Sci. USA Vol. 83, pp. 1523-1527, March 1986 Neurobiology Autoradiographic comparison of the distribution of the neutral endopeptidase "enkephalinase" and of ja and 6 opioid receptors in rat brain (enkephailnase inhibitor/enkephalin) GILLES WAKSMAN*, EDITH HAMELt, MARIE-CLAUDE FOURNI&-ZALUSKI*, AND BERNARD P. ROQUES*t *DJpartement de Chimie Organique, U 266 Institut National de la Santd et de la Recherche Mddicale, UA 498 Centre National de la Recherche Scientifique, UER des Sciences Pharmaceutiques et Biologiques, 4, avenue de l'Observatoire, 75006 Paris, France; and tCerebral Circulation and Metabolism Group, Laboratoire d'Etudes et de Recherches Synthdlabo, 92220 Bagneux, France Communicated by Jean-Pierre Changeux, October 7, 1985 ABSTRACT The neutral endopeptidase EC 3.4.24.11, also inhibitors. Although an operational re-uptake mechanism designated enkephalinase, has been visualized by in vitro cannot be definitively excluded, it is generally accepted that autoradiography using the tritiated inhibitor [3H]-N-[(2RS)-3- extracellular hydrolysis of enkephalins by the endopeptidase hydroxyaminocarbonyl-2-benzyl-1-oxopropyl]glycine, EC 3.4.24.11 represents a major mechanism for terminating ([3H]HACBO-Gly). Specific binding of [3H]HACBO-Gly (Kd = the enkephalinergic signal (8-10). However, the ability of 0.4 ± 0.05 nM) corresponding to 85% of the total binding to purified enkephalinase to degrade a variety of neuropeptides brain slices was inhibited by 1 IAM thiorphan, a selective in vitro, including substance P, cholecystokinin-(26-33) [sul- inhibitor of enkephalinase, but remained unchanged in the fated cholecystokinin (CCK)-octapeptide], and neurotensin presence of captopril, a selective inhibitor of angiotensin- (reviewed in ref. 11), raises questions concerning the selec- converting enzyme. Very high levels of [3H]HACBO-Gly bind- ing were found in the choroid plexus and the substantia nigra. tive involvement of the neutral endopeptidase in enkephalin High levels were present in the caudate putamen, globus metabolism in vivo. A plausible hypothesis is that the pallidus, nucleus accumbens, olfactory tubercle, and in the specificity of enkephalinase action in vivo is determined by substantia gelatinosa of the spinal cord. Moderate densities the selective association of the enzyme with enkephalinergic were found in parts of the amygdala, the periaqueductal gray neuronal systems. matter, the interpeduncular nucleus, and the molecular layer To test this hypothesis and to obtain a better understanding of the cerebellum. The distribution of enkephalinase was of enkephalinergic function, we have compared the regional compared to that of ,u and 6 opioid receptors, selectively distributions of opioid receptors and enkephalinase in rat labeled with [3H]Tyr-D-Ala-Gly-MePhe-glycinol and [3H]Tyr- brain by autoradiography. Selective labeling of A and 8 D-Thr-Gly-Phe-Leu-Thr, respectively. In the caudate puta- receptor types (12-14) was achieved by use ofthe appropriate men, [3H]HACBO-Gly binding overlapped the clustered IA sites radiolabeled probes, [3H]DAMGE and [3H]DTLET, respec- but appeared more closely related to the diffusely distributed tively (15, 16). The enkephalinase was selectively visualized 6 sites. High levels of enkephalinase and ,u opioid binding sites with the recently described (17) potent and tritiated inhibitor were present at the level of the periaqueductal gray matter and [3H]-N-[(2RS)-3-hydroxyaminocarbonyl-2-benzyl-1-oxopro- in the substantia gelatinosa of the spinal cord, regions where pyliglycine ([3H]HACBO-Gly). The autoradiographic analy- only sparse 6 opioid receptors could be detected. The associ- sis of the neutral endopeptidase's distribution in many brain ation of enkephalinase with 6 and ,u opioid receptors in these regions is consistent with a selective role of enkephalinase in areas is consistent with the observed role of the enzyme in the termination of the enkephalinergic signal. regulating the effects of opioid peptides in striatal dopamine release and analgesia, respectively. Except for the choroid plexus and the cerebellum, the close similarity observed in MATERIALS AND METHODS numerous rat brain areas between the distribution of Chemicals. enkephalinase and that of it and/or 6 opioid binding sites could [3,5-3H]Tyr-D-Ala-Gly-MePhe-glycinol account for most of the pharmacological effects elicited by ([3H]DAMGE, 60 Ci/mmol; 1 Ci = 37 GBq) was purchased enkephalinase inhibitors. from Amersham. [3 ,5-3H]Tyr-D-Thr-Gly-Phe-Leu-Thr ([3H]DTLET, 45 Ci/mmol) (16) and [3H]HACBO-Gly were The endogenous opioid peptide enkephalins are chiefly and synthesized in our laboratory and tritiated by reduction, with rapidly metabolized in the brain (1) by both an aminopepti- 3H2, of the benzylidene precursor (17) at the Commissariat a dase activity (2, 3) and enkephalinase (4), a membrane-bound l'Energie Atomique (Saclay, France). Thiorphan was from enzyme identical to the neutral metalloendopeptidase EC our laboratory (6). Levorphanol was a gift from Hoffman-La 3.4.24.11 (5). The physiological relevance of brain enkepha- Roche Laboratories (Basel, Switzerland). linase is supported by the naxolone-reversible decrease in the Binding Procedures. Male Sprague-Dawley rats (150-200 g) were decapitated, and their brains, including the upper responsiveness to nociceptive stimuli - elicited by intracerebral administration of highly potent enkephalinase segments of the cervical spinal cord, were rapidly removed inhibitors such as thiorphan {N-[(2RS)-2-mercaptomethyl-1- and frozen in isopentane at -45°C. Coronal sections (20 ,tm oxo-3-phenylpropyl]glycine} (6) or kelatorphan {N-[(2R)-3- thick) were cut on a cryostat at -17°C, thaw-mounted onto hydroxyaminocarbonyl-2-benzyl-1-oxopropyl]-L-alanine} gelatin-coated slides, and stored at -80'C until used. All (7), a compound belonging to a new series of bidentate Abbreviations: CCK, cholecystokinin; DAMGE, [D-Ala2,N-methyl- Phe4,glycinol5]enkephalin; DTLET, Tyr-D-Thr-Gly-Phe-Leu-Thr The publication costs of this article were defrayed in part by page charge ([D-Thr2,Leu5]enkephalin-Thr6); HACBO-Gly, N-[(2RS)-3-hydroxy- payment. This article must therefore be hereby marked "advertisement" aminocarbonyl-2-benzyl-1-oxopropyl]glycine. in accordance with 18 U.S.C. §1734 solely to indicate this fact. tTo whom reprint requests should be addressed. 1523 Downloaded by guest on September 27, 2021 1524 Neurobiology: Waksman et al. Proc. Natl. Acad. Sci. USA 83 (1986) sections were warmed to room temperature just prior to As shown in Fig. LA, binding of [3H]HACBO-Gly to rat incubation for binding as described below. brain tissue sections was highly specific; the nonspecific For selective labeling of g opioid binding sites, the sections binding determined in the presence of 1 ,uM thiorphan, a were incubated with 4 nM [3H]DAMGE for 30 min at room highly potent inhibitor of enkephalinase, was 12-15% oftotal temperature in 50 mM Tris HCl (pH 7.4) as described (15). binding (Fig. 1B). In contrast, the potent and selective The 8 opioid sites were selectively labeled with 3 nM inhibitor of angiotensin-converting enzyme, captopril (19), [3H]DTLET (18). At the end of the incubation, the sections was unable to modify the specific binding of [3H]HACBO- were washed twice for 10 min in fresh buffer at 0-40C, Gly (Fig. 1C). followed by a rapid rinse in ice-cold distilled water, and then Moreover, HACBO-Gly was shown to be a selective dried under a stream of cold air. For nonspecific binding, the inhibitor of enkephalinase with a Ki of approximately 0.4 nM sections were incubated as above with either [3H]DAMGE or but greater than 30 nM for the dipeptidyl aminopeptidase and [3H]DTLET but in the presence of 10 1LM levorphanol. In 1 uM for other brain metallopeptidases, such as aminopep- both cases, nonspecific binding accounted for <10%1 of total tidase M and angiotensin-converting enzyme (17). binding in all brain regions studied. Autoradiographic Localization of [H]HACBO-Gly Binding The enkephalinase was labeled with 3 nM [3H]HACBO- Sites in Rat Brain. [3H]HACBO-Gly binding sites were found Gly for 60 min at room temperature in 50 mM Tris HCl (pH to be discretely distributed in rat brain (Fig. 1A and Table 1), 7.4). At the end of the incubation, the sections were washed with the highest concentrations in the choroid plexus, in fresh ice-cold buffer for 1 min followed by two 5-min substantia nigra, caudate putamen, globus pallidus, olfactory rinses, rapidly washed in ice-cold distilled water, and imme- tubercle, nucleus accumbens, and the substantia gelatinosa diately dried. Nonspecific binding was determined in sections of the spinal cord. A second group of structures containing incubated as above but in the presence of 1 AM thiorphan and moderate levels of [3H]HACBO-Gly binding included parts accounted for <15% of the total binding. of the amygdala, the interpeduncular nucleus, the molecular Autoradiography. After being carefully dried, all labeled layer of the cerebellum, the periaqueductal gray matter, and sections were mounted with eight calibrated tritium stan- the hippocampus. dards and closely apposed to sheets of tritium-sensitive Interestingly, an accumulation of silver grains, intermin- Ultrofilm (LKB, Fisher) inside x-ray cassettes. The films gled with streaks of nonlabeled zones corresponding to the were exposed for 8-12 weeks at 4°C and then developed in presence of white matter tracts, was observed in the region Kodak LX-24 developer for 1.5 min at 18°C, fixed in Kodak connecting the substantia nigra and the caudate putamen L-4 fixative for 5 min, washed for 30 min under running tap (Fig. LA); this labeling was particularly dense in the area of water, and dried. the entopeduncular nucleus. Such a pattern of labeling has Quantitation of Binding Sites by Densitometry. All films been reported at the level of the nigrostriatal pathway for were analyzed by spot densitometry using a Quantimet 720 angiotensin-converting enzyme visualized with [3Hicaptopril (Cambridge Instrument Ltd., Cambridge, England).
Load more

Recommended publications
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Enkephalin Degradation in Serum of Patients with Inflammatory Bowel Diseases
    Pharmacological Reports 71 (2019) 42–47 Contents lists available at ScienceDirect Pharmacological Reports journal homepage: www.elsevier.com/locate/pharep Original article Enkephalin degradation in serum of patients with inflammatory bowel diseases a, a b Beata Wilenska *, Dagmara Tymecka , Marcin Włodarczyk , b c Aleksandra Sobolewska-Włodarczyk , Maria Wisniewska-Jarosinska , d e b a,d, Jolanta Dyniewicz , Árpád Somogyi , Jakub Fichna , Aleksandra Misicka * a Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warszawa, Poland b Department of Biochemistry, Medical University of Lodz, Łódz, Poland c Department of Gastroenterology, Medical University of Lodz, Łódz, Poland d Department of Neuropeptides, Mossakowski Medical Research Centre Polish Academy of Science, Warszawa, Poland e Campus Chemical Instrumentation Centre (CCIC), The Ohio State University, Columbus, OH, USA A R T I C L E I N F O A B S T R A C T Article history: Background: Inflammatory bowel diseases (IBD) are a group of chronic and recurrent gastrointestinal Received 18 April 2018 disorders that are difficult to control. Recently, a new IBD therapy based on the targeting of the Received in revised form 10 June 2018 endogenous opioid system has been proposed. Consequently, due to the fact that endogenous Accepted 1 August 2018 enkephalins have an anti-inflammatory effect, we aimed at investigating the degradation of serum Available online 2 August 2018 enkephalin (Met- and Leu-enkephalin) in patients with IBD. Methods: Enkephalin degradation in serum of patients with IBD was characterized using mass Keywords: spectrometry methods. Calculated half-life (T1/2) of enkephalins were compared and correlated with the Inflammatory bowel diseases disease type and gender of the patients.
    [Show full text]
  • PRODUCT INFORMATION Spinorphin Item No
    PRODUCT INFORMATION Spinorphin Item No. 29914 NH CAS Registry No.: 137201-62-8 Formal Name: L-leucyl-L-valyl-L-valyl-L-tyrosyl-L- O H O N prolyl-L-tryptophyl-L-threonine N OH O N H Synonyms: Leu-Val-Val-Tyr-Pro-Trp-Thr, O OH H LVVYPWT O O N MF: C45H64N8O10 N N O FW: 877.0 H H NH2 Purity: ≥95% UV/Vis.: λmax: 222 nm Supplied as: A crystalline solid Storage: -20°C OH Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Spinorphin is supplied as a crystalline solid. A stock solution may be made by dissolving the spinorphin in the solvent of choice, which should be purged with an inert gas. Spinorphin is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of spinorphin in these solvents is approximately 30 mg/ml. Description Spinorphin is a heptapeptide inhibitor of the enkephalin-degrading enzymes aminopeptidase, dipeptidyl aminopeptidase, angiotensin-converting enzyme (ACE), and enkephalinase (IC50s = 3.3, 1.4, 2.4, and 10 µg/ml, respectively, for monkey brain enzymes).1 It is selective for these enzymes over human serum aminopeptidase A (IC50 = >100 µg/ml), as well as porcine kidney aminopeptidase B, aminopeptidase M, dipeptidyl peptidase 1 (DPP-1), DPP-2, DPP-3, and DPP-4 (IC50s = >55 µg/ml for all). Spinorphin inhibits chemotaxis, production of reactive oxygen species (ROS), and exocytosis of glucuronidase and collagenase in polymorphonuclear neutrophils (PMNs). It potentiates enkephalin-induced action potentials in rat hippocampal slices.
    [Show full text]
  • Neprilysin Controls the Synaptic Activity of Neuropeptides in the Intercalated Cells of the Amygdala
    Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted. The final version may differ from this version. Neprilysin controls the synaptic activity of neuropeptides in the intercalated cells of the amygdala Authors: Gregoriou GC, Patel SD, Winters BL, Bagley EE Primary laboratory of origin: Discipline of Pharmacology & Charles Perkins Centre, Charles Perkins Centre D17, Downloaded from University of Sydney, Camperdown, NSW, 2006, Australia. molpharm.aspetjournals.org at ASPET Journals on October 1, 2021 1 Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted. The final version may differ from this version. Running title: Neuropeptides degradation in the amygdala Corresponding author: Elena Bagley Address: Discipline of Pharmacology & Charles Perkins Centre, Charles Perkins Centre D17, University of Sydney, Camperdown, NSW, 2006, Australia. Telephone: 61 2 93514895 Fax: N/A E-mail: [email protected] Number of pages: 31 Downloaded from Number of figures: 3 Number of references: 56 Words in abstract: 245 molpharm.aspetjournals.org Words in introduction: 486 Words in discussion: 844 Abbreviations: at ASPET Journals on October 1, 2021 ACE: angiotensin-converting enzyme ACSF: artificial cerebrospinal fluid APN: aminopeptidase N BLA: basolateral amygdala CNS: central nervous system DOR: δ-opioid receptor EPSC: excitatory post‐synaptic currents MOR: µ-opioid receptor met-enk: methione enkephalin NEP: neprilysin N/OFQ: Nociceptin/Orphanin FQ PI: peptidase inhibitors PPR: paired pulse ratio 2 Molecular Pharmacology Fast Forward. Published on June 30, 2020 as DOI: 10.1124/mol.119.119370 This article has not been copyedited and formatted.
    [Show full text]
  • Morphine Indiscriminatingly Overstimulates All Opioid Receptors Including Those Not Involved in (Morphine) Pain Control (Exogenous)
    Extensions des propriétés des inhibiteurs mixtes des enképhalinases aux douleurs de la sphère cranio-faciale. Nouvelles applications à la migraine et aux douleurs de la cornée. Bernard P. Roques Professeur Emérite, Université Paris Descartes Unité 1267 Inserm, 4 avenue de l’Observatoire, 75006 Paris. ATHS Biarritz, 1-4 Octobre 2019 CONFIDENTIAL 1 Endorphins and their receptors. Endomorphin-1 Tyr – Pro – Trp – Phe – NH2 Endomorphin-2 Tyr – Pro – Phe – Phe – NH2 2 2 Drug Discovery : designing the ideal opioid (From B.L. Kieffer, Nature (2016), 537, 170-171) 3 Three levels of pain control by endogenous opioid system (EOS) EOS EOS Attacking pain at EOS its source Relieving or reducing pain at its source More than 50% of MO effects are attributable to peripheral neurons (nociceptors) Roques, B.P., Fournié-Zaluski, M.C. and Wurm, M., Nature Reviews Drug Discovery, 2012 4 DENKIs: mechanism of action The endogenous opioid system (EOS) is present at all levels of physiological-nociceptive control i.e. periphery, spinal cord and brain Elements of the EOS are opioid receptors, enkephalins and their inactivating enzymes Dual Inhibitors of ENKephalinases (DENKIs) potentiate physiological functions of DENKI enkephalins (e.g. pain control) only on those pathways where they are tonically released Enkephalinases APN NEP No adverse effects Enkephalins Y G G F M(L) (endogenous) Opioid receptors Morphine indiscriminatingly overstimulates all opioid receptors including those not involved in (Morphine) pain control (exogenous) Adverse effects 5 Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets in a murine model of bone cancer-induced pain.
    [Show full text]
  • The Inhibition of Enkephalin Catabolism by Dual Enkephalinase Inhibitor: a Novel Possible Therapeutic Approach for Opioid Use Disorders
    Alvarez-Perez Beltran (Orcid ID: 0000-0001-8033-3136) Maldonado Rafael (Orcid ID: 0000-0002-4359-8773) THE INHIBITION OF ENKEPHALIN CATABOLISM BY DUAL ENKEPHALINASE INHIBITOR: A NOVEL POSSIBLE THERAPEUTIC APPROACH FOR OPIOID USE DISORDERS ALVAREZ-PEREZ Beltran1*, PORAS Hervé 2*, MALDONADO Rafael1 1 Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, c/Dr Aiguader 88, 08003 Barcelona, Spain, 2 Pharmaleads, Paris BioPark, 11 Rue Watt, 75013 Paris, France *Both authors participated equally to the manuscript Correspondence: Rafael Maldonado, Laboratori de Neurofarmacologia, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB), c/Dr. Aiguader, 88, 08003 Barcelona, Spain. E-mail: [email protected] ABSTRACT Despite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoiding the classical opioid-like side effects. Dual Enkephalinase Inhibitors (DENKIs) physiologically activate the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins, increasing their half-lives and physiological actions. The activation of opioid receptors by the increased enkephalin levels, and their well-demonstrated safety, suggest that DENKIs could represent a novel analgesic therapy and a possible effective treatment for acute opioid withdrawal, as well as a promising alternative to opioid substitution therapy minimizing side effects. This new pharmacological class of compounds could bring effective and safe medications avoiding the This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.
    [Show full text]
  • Citation Classics and Trends in the Field of Opioids: a Bibliometric Analysis
    Open Access Original Article DOI: 10.7759/cureus.5055 Citation Classics and Trends in the Field of Opioids: A Bibliometric Analysis Hira F. Akbar 1 , Khadijah Siddiq 2 , Salman Nusrat 3 1. Internal Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, PAK 2. Internal Medicine, Civil Hospital Karachi, Dow University of Health Sciences, Karachi, PAK 3. Gasteroenterology, University of Oklahoma Health Sciences Center, Oklahoma City, USA Corresponding author: Hira F. Akbar, [email protected] Abstract Introduction Bibliometric analysis is one of the emerging and latest statistical study type used to examine and keep a systemic record of the research done on a particular topic of a certain field. A number of such bibliometric studies are conducted on various topics of the medical science but none existed on the vast topic of pharmacology - opioids. Hence, we present a bibliometric analysis of the ‘Citation Classics’ of opioids. Method The primary database chosen to extract the citation classics of opioids was Scopus. Top 100 citation classics were arranged according to the citation count and then analyzed. Results The top 100 citation classics were published between 1957 and 2013, among which seventy-two were published from 1977 to 1997. Among all nineteen countries that contributed to these citation classics, United States of America alone produced sixty-three classics. The top three journals of the list were multidisciplinary and contained 36 citation classics. Endogenous opioids were the most studied (n=35) class of opioids among the citation classes and the most studied subject was of the neurosciences. Conclusion The subject areas of neurology and analgesic aspects of opioids are well established and endogenous and synthetic opioids were the most studied classes of opioids.
    [Show full text]
  • Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
    Molecular Pharmacology Fast Forward. Published on June 2, 2020 as DOI: 10.1124/mol.120.119388 This article has not been copyedited and formatted. The final version may differ from this version. File name: Opioid peptides v45 Date: 5/28/20 Review for Mol Pharm Special Issue celebrating 50 years of INRC Five decades of research on opioid peptides: Current knowledge and unanswered questions Lloyd D. Fricker1, Elyssa B. Margolis2, Ivone Gomes3, Lakshmi A. Devi3 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; E-mail: [email protected] 2Department of Neurology, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, San Francisco, CA 94143, USA; E-mail: [email protected] 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Annenberg Downloaded from Building, One Gustave L. Levy Place, New York, NY 10029, USA; E-mail: [email protected] Running Title: Opioid peptides molpharm.aspetjournals.org Contact info for corresponding author(s): Lloyd Fricker, Ph.D. Department of Molecular Pharmacology Albert Einstein College of Medicine 1300 Morris Park Ave Bronx, NY 10461 Office: 718-430-4225 FAX: 718-430-8922 at ASPET Journals on October 1, 2021 Email: [email protected] Footnotes: The writing of the manuscript was funded in part by NIH grants DA008863 and NS026880 (to LAD) and AA026609 (to EBM). List of nonstandard abbreviations: ACTH Adrenocorticotrophic hormone AgRP Agouti-related peptide (AgRP) α-MSH Alpha-melanocyte stimulating hormone CART Cocaine- and amphetamine-regulated transcript CLIP Corticotropin-like intermediate lobe peptide DAMGO D-Ala2, N-MePhe4, Gly-ol]-enkephalin DOR Delta opioid receptor DPDPE [D-Pen2,D- Pen5]-enkephalin KOR Kappa opioid receptor MOR Mu opioid receptor PDYN Prodynorphin PENK Proenkephalin PET Positron-emission tomography PNOC Pronociceptin POMC Proopiomelanocortin 1 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Improving Naltrexone Compliance and Outcomes with Putative Pro
    Journal of Systems and Integrative Neuroscience Research Article ISSN: 2059-9781 Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual Kenneth Blum1*, Lisa Lott2, David Baron1, David E Smith3, Rajendra D Badgaiyan4 and Mark S Gold5 1Western University Health Sciences, Graduate College, Pomona, CA, USA 2Division of Behavioral Precision Management, Geneus Health, LLC, San Antonio, TX, USA 3Department of Pharmacology, University of California San Francisco School of Medicine, San Francisco, CA, USA 4Department of Psychiatry, Icahn School of Medicine Mt Sinai, New York, NY, USA and Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital, San Antonio, TX, Long School of Medicine, University of Texas Medical Center, San Antonio, TX, USA 5Department of Psychiatry, Washington University School of Medicine, St. Louis, Mo, USA Abstract A recent analysis from Stanford University suggested that without any changes in currently available treatment, prevention, and public health approaches, we should expect to have 510,000 deaths from prescription opioids and street heroin from 2016 to 2025 in the US. In a recent review, Mayo Clinic Proceedings (October 2019), Gold and colleagues at Mayo Clinic reviewed the available medications used in opioid use disorders and concluded that in private and community practice adherence is more important as a limiting factor to retention, relapse, and repeat overdose. It is agreed that the primary utilization of known opioid agonists like methadone, buprenorphine and naloxone combinations, while useful as a way of reducing societal harm, is limited by 50% of more discontinuing treatment within 6 months, their diversion, and addiction liability.
    [Show full text]
  • Cayman Pain Research
    Pain Research The development of novel pain therapeutics relies on understanding the highly complex nociceptive signaling pathways. Cayman offers a select group of tools to study TRP ion channels, purinergic receptors, voltage-gated ion channels, and various G protein-coupled receptors (GPCRs) that are known to be expressed by nociceptive primary afferent nerves. Modulators of glutamate, GABA, and nicotinic acetylcholine receptors are also available. Pain Signal Pain Transmission Primary nociceptor afferents release neurotransmitters such as glutamate and prostaglandins, which bind to specific Glutamate, prostaglandins, etc. receptors on the postsynaptic membrane to transmit a pain signal. 2+ glutamate Ca prostaglandins cannabinoids opioids The antinociceptive response includes Mg2+ EP1 AMPA NMDA inhibitory interneurons, signaling via GABA CB OP receptors, that activate μ-opioid receptors, + Na Ca2+ among others. + 2+ 5-HT K Ca Action potentials Na+ GABA Inhibitory Inhibitory pathways descending from interneuron the brainstem release neurotransmitters Descending neuron from such as serotonin (5-HT) or activate small brainstem opioid-containing interneurons in the spinal dorsal horn to release opioid peptides. Pain Signal Image adapted from: Olesen, A.E., Andresen, T., Staahl, C., et al. Pharmacol. Rev. 64(3), 722-779 (2012). Ligand-Gated Ion Channels TRP Ion Channel Agonists and Antagonists Item No. Product Name Summary A competitive antagonist of capsaicin activation of TRPV1 (IC s = 24.5 and 85.6 nM for human 14715 AMG 9810 50 and rat,
    [Show full text]
  • Małgorzata Katarzyna Sobocińska Faculty of Chemistry Department of Molecular Biotechnology Laboratory of Chemistry of Biological Macromolecules
    Małgorzata Katarzyna Sobocińska Faculty of Chemistry Department of Molecular Biotechnology Laboratory of Chemistry of Biological Macromolecules Supervisor: Dr. hab. Elżbieta Kamysz, UG Prof. SUMMARY OF DOCTORAL DISSERTATION “Synthesis and biological studies of endogenous enkephalinase inhibitors and their analogues as potential therapeutic substances in therapy of inflammatory bowel disease and visceral pain” Pharmacological treatment and/or maintenance of remission in inflammatory bowel disease (IBD) which includes Crohn’s disease (CD) and ulcerative colitis (UC) is currently one of the biggest challenges in the field of gastroenterology. The main goal in anti-IBD therapy includes management of inflammation and alleviation of other clinical symptoms like intestinal motility disorder or visceral pain. One of the recent trends in the research of new forms of IBD therapy focuses on the endogenous opioid system. Endogenous opioid peptides such as enkephalins (Met-enkephalin and Leu-enkephalin) participate in the antinociception [1], regulation of gastrointestinal motility [2], regulation of the immune system [3, 4], cardiovascular system [5, 6] anti-inflammatory, hormonal and behavioural responses [7,8]. The action of endogenous opioids in the living organism is strongly regulated by their metabolism and the half-life of enkephalins in the human plasma can be measured within minutes [9], which significantly hampers their pharmacological application. Aminopeptidase N (APN), neutral endopeptidase (NEP), dipeptidyl peptidase III (DPP III) and angiotensin- converting enzyme (ACE) are the major enkephalin-degrading enzymes. These proteases are widely distributed in the human body and are significantly involved in physiological modulation and pathophysiological processes in the gastrointestinal tract [10]. Rat sialorphin (Gln-His-Asn-Pro-Arg), human opiorphin (Gln-Arg-Phe-Ser-Arg) and bovine spinorphine (Leu-Val-Val-Tyr-Pro-Trp-Thr) are endogenous inhibitors of enkephalin-degrading enzymes.
    [Show full text]
  • Pharmacological Characterisation of the Highly Nav1.7 Selective Spider Venom Peptide Pn3a Received: 29 September 2016 Jennifer R
    www.nature.com/scientificreports OPEN Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a Received: 29 September 2016 Jennifer R. Deuis1, Zoltan Dekan1, Joshua S. Wingerd1, Jennifer J. Smith1, Accepted: 12 December 2016 Nehan R. Munasinghe2, Rebecca F. Bhola2, Wendy L. Imlach2, Volker Herzig1, Published: 20 January 2017 David A. Armstrong3, K. Johan Rosengren3, Frank Bosmans4, Stephen G. Waxman5, Sulayman D. Dib-Hajj5, Pierre Escoubas6, Michael S. Minett7, Macdonald J. Christie2, Glenn F. King1, Paul F. Alewood1, Richard J. Lewis1, John N. Wood7 & Irina Vetter1,8 Human genetic studies have implicated the voltage-gated sodium channel NaV1.7 as a therapeutic target for the treatment of pain. A novel peptide, μ-theraphotoxin-Pn3a, isolated from venom of the tarantula Pamphobeteus nigricolor, potently inhibits NaV1.7 (IC50 0.9 nM) with at least 40–1000- fold selectivity over all other NaV subtypes. Despite on-target activity in small-diameter dorsal root ganglia, spinal slices, and in a mouse model of pain induced by NaV1.7 activation, Pn3a alone displayed no analgesic activity in formalin-, carrageenan- or FCA-induced pain in rodents when administered systemically. A broad lack of analgesic activity was also found for the selective NaV1.7 inhibitors PF- 04856264 and phlotoxin 1. However, when administered with subtherapeutic doses of opioids or the enkephalinase inhibitor thiorphan, these subtype-selective NaV1.7 inhibitors produced profound analgesia. Our results suggest that in these inflammatory models, acute administration of peripherally restricted NaV1.7 inhibitors can only produce analgesia when administered in combination with an opioid. The pore-forming subunits of voltage-gated sodium channels (NaV) are integral membrane proteins that allow influx of sodium ions, which is essential for action potential generation and propagation in electrically excitable cells.
    [Show full text]